Skip to main content
SpringerLink
Log in

A Novel Stability-Indicating Method for Determination of Related Substances of Montelukast Sodium in a Pharmaceutical Dosage Form Using RP-HPLC

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

The main aim is to develop a simple, rugged, and sensitive method for determining the Montelukast Sodium-related impurities in a tablet dosage form using reverse-phase high-performance liquid chromatography (RP-HPLC) method. Chromatographic separation on the Agilent Eclipse XDB C18 (octadecylsilane) column of the dimension (100 mm × 4.6 mm, 5 µm) was carried out in the gradient mode with triethylamine and acetonitrile in various combinations and adjusted to a pH of 6.60 using phosphoric acid. The mobile phase was pumped at a flow rate of 1.0 mL min−1 and the analyte was monitored with a UV detector at a wavelength of 220 nm. The method was developed and validated under the stress conditions such as acidic, basic, peroxide, thermal, photolytic, and humidity degradation, respectively. Under the above conditions, oxidative degradation was performed which served as the system suitability solution providing a resolution of 2.5 between the Impurity 3 (retention time = 13.8 min) and Montelukast Sodium (retention time = 24.2 min). The method was validated with respect to specificity, linearity, precision, accuracy, limit of detection, and limit of quantification provided by the ICH guidelines. Results of linear regression analysis of the calibration plot revealed a good linear relationship between response and concentration with a correlation coefficient value of r2 = 0.9999. The accuracy of known impurities was obtained in the range of 94–108%. From the analysis, their LOD and LOQ values for impurities were measured and found to be 0.007 and 0.025 μg g−1, respectively. Chromatographic interference was not found during the degradation and excipients were detected from the tablet. The proposed method was successfully used to estimate the Montelukast Sodium-related impurities in a tablet dosage form.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Saeed-Ul-Hassan S, Ahsan-Ul-Haq Athe R, Ansari MT, Tariq I, Karim S (2013) Determination of Montelukast Sodium in raw material and solid dosage form using reverse phase HPLC. Asian J Chem 25(13):7481–7484

    Article  CAS  Google Scholar 

  2. C. N. Nalini, Vinoth Kumar (2020) A Review of Different Analytical Techniques for Fexofenadine Hydrochloride and Montelukast Sodium in Different Matrices. Critical Reviews in Analytical Chemistry

  3. Revathi R, Ethiraj T, Thenmozhi P, Saravanan VS, Ganesan V (2011) High performance liquid chromatographic method development for simultaneous analysis of doxofylline and montelukast sodium in a combined form. Pharma Methods 2(4):223–238

    Article  CAS  Google Scholar 

  4. Badulla W, Arli G (2017) Comparative study for direct evaluation of montelukast sodium in tablet dosage form by multiple analytical methodologies. Rev Roum Chim 62(2):173–179

    Google Scholar 

  5. Garg LK, Reddy VS, Sait SS, Krishnamurthy T, Jafer Vali S, Malleswara Reddy A (2013) Quality by design: design of experiments approach prior to the validation of a stability-indicating HPLC method for montelukast. Chromatographia 2013(76):1697–1706

    Article  Google Scholar 

  6. Ali S, Gupta M (2019) Method development and validation for the simultaneous estimation of montelukast sodium and levocetirizine hydrochloride tablet using RP-HPLC. J Pharm Sci Res 11(8):2998–3000

    CAS  Google Scholar 

  7. Shakya AK, Arafat TA, Hakooz NM, Abuawwad AN, Al-Hroub H, Melhim M (2014) High-performance liquid chromatographic determination of montelukast sodium in human plasma: application to bioequivalence study. Acta Chromatogr 26(3):457–472

    Article  Google Scholar 

  8. Roman J, Breier AR, Steppe M (2011) Stability indicating LC method to determination of sodium montelukast in pharmaceutical dosage form and its photodegradation kinetics. J Chromatogr Sci 49:540–546

    Article  CAS  Google Scholar 

  9. Bhagade SR (2013) Spectrophotometric estimation of montelukast from bulk drug and tablet dosage form. IJPSR 4(11):4432–4434

    Google Scholar 

  10. Singh RM, Saini PK, Mathur SC, Singh GN, Lal B (2010) Development and validation of a RP-HPLC method for estimation of montelukast sodium in bulk and in tablet dosage form. Indian J Pharm Sci 72(2):235–237

    Article  CAS  Google Scholar 

  11. Flor S, Juan MH, Tripodi V, Lucangioli S (2016) Development of an enantioselective capillary electrophoretic method for the simultaneous determination of montelukast enantiomeric and diastereoisomeric forms and its main degradation product. Electrophoresis 37:2420–2428

    Article  CAS  Google Scholar 

  12. Çölkesen B, Öztürk F, Erden PE (2016) Electroanalytical characterization of montelukast sodium and its voltammetric determination in pharmaceutical dosage form and biological fluids. J Braz Chem Soc 27(5):849–856

    Google Scholar 

  13. Saravanan M, Siva Kumari K, Pratap Reddy P, Naidu MN, Moses Babu J, Srivastava AK, Lakshmi Kumar T, Chandra Sekhar BVVN, Satyanarayana B (2008) Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium. J Pharm Biomed Anal 48(2008):708–715

    Article  CAS  Google Scholar 

  14. USP Pharmacopeia Monograph for Montelukast Sodium Tablets May 2020

  15. ICH Harmonised Tripartite Guideline (1994) Validation of Analytical Procedures: Text and Methodology Q2 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use

  16. ICH Harmonised Tripartite Guideline (2006) Impurities in new drug substances Q3A (R2). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use

  17. ICH Harmonised Tripartite Guideline (2006) Impurities in new drug products Q3B (R2). International Conference on Harmonisation of Technical Requirements for registration of Pharmaceuticals for Human use

  18. European pharmacopoeia 5.0 5.10. Impurities in Substances for Pharmaceutical use

  19. Narin I, Sarioglan S, Anilanmert B, Sari H (2010) pK a determinations for montelukast sodium and levodropropizine. J Sol Chem 39(10):1582–1588

    Article  CAS  Google Scholar 

  20. Van Deemter J, Zuiderweg F, Klinkenberg AV (1956) Longitudinal diffusion and resistance to mass transfer as causes of nonideality in chromatography. Chem Eng Sci 5(6):271–289

    Article  Google Scholar 

  21. Ranjan OP, Nayak UY, Reddy MS, Dengale SJ, Musmade PB, Udupa N (2013) Development and validation of RP-HPLC method with ultraviolet detection for estimation of montelukast in rabbit plasma: application to preclinical pharmacokinetics. J Young Pharm 5(4):133–138

    Article  CAS  Google Scholar 

  22. ⟨1086⟩ Impurities in Drug Substances and Drug Products, USP 40 page 1270; and PF 41(3) [May–June 2015]

Download references

Funding

The author, Dr. K. Venkatachalam is extremely thankful for the financial help for the DST-SERB project of the Department of Science and Technology, India (Ref. No EEQ/2016/000559, Date: 06.02.2017).

Author information

Authors and Affiliations

  1. Department of Analytical Chemistry, University of Madras, Guindy Campus, Chennai, 60025, Tamil Nadu, India

    K. Samuel Barnabas, S. Prashanna Suvaitha, G. Dhinagaran & K. Venkatachalam

Authors
  1. K. Samuel Barnabas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Prashanna Suvaitha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Dhinagaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Venkatachalam
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KSB—conceptualization, methodology, writing—original draft preparation, and writing—reviewing and editing. SPS—investigation, reviewing and editing. GD—data curation. KV—writing-review, visualization, supervision and project administration.

Corresponding author

Correspondence to K. Venkatachalam.

Ethics declarations

Conflict of interest

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barnabas, K.S., Suvaitha, S.P., Dhinagaran, G. et al. A Novel Stability-Indicating Method for Determination of Related Substances of Montelukast Sodium in a Pharmaceutical Dosage Form Using RP-HPLC. Chromatographia 84, 645–662 (2021). https://doi.org/10.1007/s10337-021-04045-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-021-04045-8

Keywords

Search

Navigation